Positions

Selected Publications

Academic Article

Year Title Altmetric
2018 Outcome for pediatric acute promyelocytic leukemia patients at Children's Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance).Medical and Pediatric Oncology.  e27542. 2018
2018 Acute myelogenous leukemia in adolescents and young adults.Medical and Pediatric Oncology.  65:e27089. 2018
2018 Risk Markers for Significant Bleeding and Thrombosis in Pediatric Acute Promyelocytic Leukemia; Report From the Children's Oncology Group Study AAML0631.Journal of Pediatric Hematology/Oncology2018
2018 Quality Initiative to Improve time to Antibiotics for Febrile Pediatric Patients with Potential Neutropenia.Pediatric Quality and Safety.  3:e095. 2018
2018 Incidence and outcomes of paediatric myelodysplastic syndrome in the United States.British Journal of Haematology.  180:898-901. 2018
2018 Blinatumomab activity in a patient with Down syndrome B-precursor acute lymphoblastic leukemia.Medical and Pediatric Oncology.  65. 2018
2017 Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631.Journal of Clinical Oncology.  35:3021-3029. 2017
2017 Extramedullary Relapse of Acute Lymphoblastic Leukemia Presenting as Abnormal Uterine Bleeding: A Case Report.Journal of Pediatric and Adolescent Gynecology.  30:431-434. 2017
2016 Management of relapsed and refractory childhood acute promyelocytic leukaemia: recommendations from an international expert panel.British Journal of Haematology.  175:588-601. 2016
2016 Protocol for Reducing Time to Antibiotics in Pediatric Patients Presenting to an Emergency Department With Fever and Neutropenia: Efficacy and Barriers.Pediatric Emergency Care.  32:739-745. 2016
2015 Ethnic variation of TET2 SNP rs2454206 and association with clinical outcome in childhood AML: a report from the Children's Oncology Group.Leukemia.  29:2424-2426. 2015
2015 Inclusion of Adolescents and Young Adults in Cancer Clinical Trials.Seminars in Oncology Nursing.  31:197-205. 2015
2014 Treatment of paediatric APL: how does the therapeutic approach differ from adults?Baillieres Clinical Haematology.  27:69-78. 2014
2013 Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report.Leukemia.  27:238-241. 2013
2012 FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group.Medical and Pediatric Oncology.  59:662-667. 2012
2011 Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group.Medical and Pediatric Oncology.  57:204-209. 2011

Chapter

Year Title Altmetric
2017 Acute Myelogenous Leukemia.  135-149. 2017

Principal Investigator On

  • AHOD1331-A Randomized Phase III Study of Brentuximab Vedotin for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma in Children and Adolescents  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2025
  • AALL 1521; A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High-Risk CRLF2- Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Lukemia  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2016 - 2024
  • AALL1621- A Phase 2 Study of Inotuzumab Ozogamicin (NSC#772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+B-Acute Lymphoblastic Leukemia(B-ALL)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2022
  • A Phase 2 Multicenter, Single-Arm, Open-Label Study to Evaluate the Activity, Safety and Pharmacokinetics of Lenalidomide (Revlimid®) in Pediatric Subjects from 1 To < 18 Years of Age with Relapsed or Refractory Acute Myeloid Leukemia  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2016 - 2021
  • AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#100135, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2015 - 2020
  • St. Baldrick's Foundation Supplemental Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2020
  • ALTE11C2 Study - Health Effects after Antracycline and Radiation Therapy (HEART) - Dexazoxane and Prevention of Antracycline-Related Cardiomyopathy  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2019
  • ALTE11C2-Health Effects after Anthracycline and Radiation Therapy (HEART) - Dexazoxane and Prevention of Antracycline-Related Cardiomyopathy  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2019
  • Intergroup Trial for Children or Adolescents with B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2019
  • Per Case Reimbursement: COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2019
  • AALL0434-Novartis Pharmaceuticals Corporation  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2019
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2019
  • Workload Intensity  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2019
  • Committee Leadership: NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Acute Myeloid Leukemia Steering Committee  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2016 - 2019
  • Committee Leadership: NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Adolescent-Young Adult Committee Young Investigator  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2016 - 2019
  • Study Chair: NIH National Clinical Trials Network (NCTN) Grant (U10CA18086) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2014 - 2019
  • CTSU: Phase ll Supplemental Payments (N02-CM-62212)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2019
  • CA 180-372, AALL1122 A Phase 2, Multi-Center, Historically Controlled Study Of Dasatinib Added To Standard Chemotherapy For Relapsed/Refractory Ph+ALL  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2018
  • Private Grant  awarded by Pfizer Pharmaceuticals 2016 - 2017
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2017
  • TET2 Mutation as a Prognostic Marker in Pediatric AML: A Leukemia Biology Study of AAML0531 From the Children's Oncology Group  awarded by KAUL PEDIATRIC RESEARCH INSTITUTE 2012 - 2015
  • Genetic Predictors of AML Treatment Response  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2014 - 2015
  • Investigator On

  • ADVL 1711: A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2022
  • AHOD1721, Risk-based, Response-Adapted, Phase ll Open- Label Trail of Nivolumab+Brentuximab Vedotin(N+Bv) for Children,Adolescents, and Young Adults with Relapsed/ Refractory (R/R) CD30+ Classic Hodgkin Lymphoma (cHL) after Failure of First -Line Therapy, followed by Brentuximab+Bendamustine(Bv+B) for participants with a suboptimal response;CheckMate 744:Checkpoint Pathway and Nivolumab Clinical Trail Evaluation.  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2022
  • ADVL 1615: A phase 1 Study of Pevonedistat (MLN4924), A Cullin Ligase Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refactory Solid Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2022
  • ADVL1721: A Non-Randomized, Open Label, Multi-Center, Phase 1/11 Study of P13K Inhibitor Copanlisib in Pediatric Patients with Relapsed/Refactory Solid Tumors or Lymphoma  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2022
  • ADVL1722: A Phase 2, Multicenter, Open- Label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects with Relapsed/Refractory  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2022
  • Project Everychild APEC14B1  awarded by CHILDREN'S ONCOLOGY GROUP 2015 - 2020
  • Cookies for Kids' Cancer Phase 1 Supplemental  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2020
  • A Phase 3 Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC # 606869) in the Very High Risk Stratum  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2014 - 2020
  • NIH COG Phase I Grant  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2020
  • ADVL 1515: A Phase 1 Study of LY2606368, A CHK 1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2019
  • ADVL1412, A Phase 1/2 Study of Nivolumab in Children Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2019
  • Per Case Reimbursement and Patient Studies Funds: NIH COG Phase 1 Grant  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2019
  • AAML 1031 - Bayer  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2017 - 2019
  • ADVL1416: A Phase 1 Study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid Tumors, Including CNS Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2018 - 2019
  • Per Case Reimbursement: COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2014 - 2018
  • STUDY: CA180-372: PH II Pediatric - Ph+ ALL  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2012 - 2018
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2014 - 2018
  • St. Baldricks Fdn Supplemental Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2012 - 2018
  • WORKLOAD INTENSITY – NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2014 - 2018
  • AHOD1331 A Randomized Phase III Study of Brentuximab Vedotin (IND#117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2016 - 2018
  • Intergroup Trial for Children or Adolescents with B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2013 - 2017
  • CTSU: Phase II Supplemental Payments (N02-CM-62212)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2012 - 2017
  • Novel Methods to Detect Gene-Environment Interactions in Treatment-Related Brain Tumors Among Childhood Cancer Survivors  awarded by University of Wisconsin-Milwaukee 2015 - 2016
  • CCOP Per Case Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2013 - 2015
  • BIQSFP-COG AALL1131 11XS189 Per Case Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2012 - 2015
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2014 - 2015
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2014
  • AAML 1031 - A Phase III Randomized Trial for Patients with De Novo AML Using Bortezomib (NSC# 681239) and Sorafenib (BAY 43-9006, NSC# 724772) for Patients with High Allelic Ratio FLT2/ITD  awarded by CHILDREN'S ONCOLOGY GROUP 2014
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2013 - 2014
  • COG Per Case Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2012 - 2014
  • Education And Training

  • Bachelor of Arts in Biomedical Sciences, Brown University
  • Doctor of Medicine, Vanderbilt University
  • Full Name

  • Matthew Kutny
  • Blazerid

  • mkutny